



CAR-T Cell Treatment for Patients with Glypican-3 (GPC3) Positive HCC (A Type of Liver Cancer)

Investigators at the National Cancer Institute (NCI) are enrolling patients with advanced hepatocellular cancers (HCC), in a clinical trial using engineered immune cells, also known as chimeric antigen receptor T-cells or CAR-T cells. In this study, your immune T-cells are collected and modified to target Glypican-3 (GPC3), a protein marker found on the surface of HCC tumors. Researchers hope the altered cells will help identify and fight the cancer cells.

This study involves

- Imaging scans of the chest, abdomen, and pelvis
- A biopsy of your tumor to confirm that it is GC3 positive
- Leukapheresis - a procedure done to collect white blood cells
- At least a nine-day inpatient stay at the NIH

You may be eligible if you

- Are ≥ 18 years of age and have a laboratory-confirmed diagnosis of HCC
- Have failed or progressed through prior first line of standard therapy, OR
- Have been intolerant of the standard of care for HCC
- Are not pregnant or planning to become



For more information or to enroll, contact the NIH Clinical Center Office of Patient Recruitment and mention study # 21-C-0030



Toll Free: **800-411-1222**
TTY users dial 7-1-1



ccopr@nih.gov



<https://go.usa.gov/xtErY>



NIH...Turning Discovery Into Health®

NIH NATIONAL CANCER INSTITUTE
Center for Cancer Research